Literature DB >> 27461931

Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient.

Aya Tanaka1, Kuniko Ikinaga1, Eiji Kiyohara1, Atsushi Tanemura1, Mari Wataya-Kaneda1, Ryuta Fujimura2, Masayuki Mizui2, Yoshitaka Isaka2, Ichiro Katayama1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27461931     DOI： 10.1111/1346-8138.13538

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

Review 1.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

2.  Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report.

Authors:  Qingjiang Hu; Hirofumi Hasuda; Kenji Ueki; Akihiro Tsuchimoto; Yoko Zaitsu; Yasuo Tsuda; Yuichi Hisamatsu; Yuichiro Nakashima; Koji Ando; Yasue Kimura; Eiji Oki; Masaki Mori
Journal:  Int Cancer Conf J       Date:  2020-05-22

3.  Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

Authors:  James W Smithy; Lauren M Moore; Vasiliki Pelekanou; Jamaal Rehman; Patricia Gaule; Pok Fai Wong; Veronique M Neumeister; Mario Sznol; Harriet M Kluger; David L Rimm
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

4.  Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy.

Authors:  Alison Taylor; Christopher E Rudd
Journal:  J Immunol Sci       Date:  2019-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.